A phase II trial of ProscaVax in advanced late-stage prostate cancer patients
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs PSA-IL2-GM-CSF vaccine (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Mar 2018 According to an OncBioMune Pharmaceuticals media release, the company has selected Theradex as its contract research organization (CRO) for this and other planned phase 2 clinical trial (261722).
- 28 Feb 2018 According to an OncBioMune media release, full protocol for this trial has been submitted to Urology Centers of North Texas (UCNT) for review. Upon review by UCNT, OncBioMune management will make any requisite adjustments and submit the protocol to the U.S. Food and Drug Administration.
- 26 Feb 2018 According to an OncBioMune media release, the company is preparing the protocol for this trial for FDA submission. For FDA approval the company will use a central IRB (Institutional Review Board), as central IRBs move much faster than most university IRBs.